Xueba’s medical black technology system

Chapter 163 The data is thrown directly in the face

Is this a cure?
The woman was stunned and couldn't react for a while.

She originally thought that given her husband's current condition, getting better would be the best outcome.

But the director's answer still exceeded the woman's psychological expectations, which made her feel like she was dreaming.

The director reminded: "However, even if you are cured, you cannot relax your vigilance. Every once in a while, remember to ask your husband to come over for a check-up."

After giving some instructions to women.The woman stood up numbly and prepared to leave.

But when she walked to the door, the woman seemed to remember something. She quickly turned around and bowed to the director: "Thank you, doctor. Thank you so much, doctor."

The director smiled helplessly: "I told you, the person you want to thank is not me, but the young man who developed the drug."

"I see, doctor."

After thanking her, the woman walked out of the consulting room, and at the door of the consulting room, the two brothers and sister were sitting on the bench waiting.

After seeing the two brothers and sister, the woman held them in her arms.

"Mom, why are you crying again?" The little girl seemed to have noticed something and asked with some confusion.

The woman smiled and rubbed the little girl's head: "Mom is so happy, my daughter. Mom will take you to eat ice cream today, okay?"

After hearing the woman's words, the little girl was stunned for a moment, but then she seemed to realize something, her eyes suddenly lit up, and she nodded vigorously.

At the same time, news about the effectiveness of PD-1/TIGIT inhibitors in clinical trials quickly spread to various lung cancer patient groups.

Many of these patient groups have applied to participate in clinical trials of drugs.

After experiencing the miraculous effects of the medicine, many patients were naturally excited and shared their experiences in the group.

This made the group of patients, who had always been quiet, suddenly become excited.

"What I said at the beginning was that I believed in God Lu. No matter what his abilities are, there is nothing else that is unworthy of belief."

"I knew that Lu Shen would never let us patients down."

"Fortunately, I resisted. I didn't believe the nonsense in that report and bought sugemalimab."

Groups of patients beat gongs and drums and rushed around to tell each other.

This matter quickly aroused heated discussion among many people. While discussing the drug, many people also did not forget to pull out Moco's sugalimab and step on it.

After all, the high price of sugalimab has already caused dissatisfaction among many people. At this time, it was natural to pull out Moco Company and scold it.

This made Moco Company quickly pay attention to this matter.

Moco quickly issued a statement on the matter.

"The company has published clinical trial data on its official website. In the third phase clinical trial, the ORR of sugalimab was as high as 84%, and the drug target is PD-1. This is among the current mainstream anti-lung cancer drugs. An extremely outstanding result.”

“If a certain drug is miraculous in the treatment of lung cancer in clinical trials, why is it so late to publish the clinical trial data after the clinical trials are completed?”

The so-called ORR, also known as objective response rate, refers to the proportion of patients whose tumor size has shrunk to a predetermined range after clinical drug treatment among the total number of patients.

This indicator means whether the drug can really control the disease. Therefore, in clinical trials of cancer drugs, ORR is often the most critical indicator to evaluate the efficacy of cancer drugs.

The ORR is as high as 84%, which means that 84% of lung cancer patients have their conditions effectively controlled in clinical practice. This level of treatment effect is truly outstanding.This is also the reason why Moco Company can publish the clinical data of Shugli drug with such confidence.

At the end of this statement, Moco Company did not forget to make some weird remarks to Lu Liang, implying that Lu Liang did not dare to actually publish the clinical trial data.

As soon as Moko issued this statement, the voice on the Internet suddenly became much quieter, and many people were also silenced.

After all, hearing is in vain and seeing is believing. Without clinical trial data, no matter how powerful a rebuttal is, it will be in vain.

However, although the Internet is quiet, Moco Company is in chaos at this moment.

Moco Company, in the conference room.

As rumors spread about PD-1/TIGIT inhibitors in clinical trials, this matter directly affected the sensitive nerves of shareholders, and an emergency meeting was immediately convened.

At this moment, the atmosphere in the conference room became extremely depressed, especially Zheng Yi, whose face looked particularly ugly at this moment.

Because she was the one who promised that Sugemalimab’s drug would definitely be better than Lu Liang’s drug, and convinced all shareholders not to reduce the price of Sugemalimab.

Therefore, now that this incident has occurred, all the pressure from the entire board of directors has fallen on Zheng Yi.

Everyone is now holding Zheng Yi accountable.

Dai Yang looked at Zheng Yi and asked sternly: "Dr. Zheng, don't you have anything to explain about this kind of thing?"

Zheng Yi took a deep breath and replied: "Chairman, I think it's too early to draw a conclusion now. Since their clinical trial has ended, why not just publish the data."

"This doesn't exactly mean that their clinical data is not as good as ours, and they feel guilty."

"As for those remarks outside, they are just rumors and gossip. I don't think they need to be taken seriously."

After listening to Zheng Yi's analysis, the shareholders fell silent. After all, Zheng Yi's analysis was quite reasonable.

Of course, the most important thing is that they are all grasshoppers on the same line now, so they can only trust Zheng Yi.

After seeing that the shareholders stopped talking, Zheng Yigang was about to breathe a sigh of relief.

However, at this moment, the door to the conference room was suddenly pushed open, and the secretary slowly walked in.

This scene stunned several shareholders present. You must know that during their meeting, they discussed company secrets, so other employees were prohibited from entering or exiting the meeting room.

Therefore, when they saw Secretary Zheng Yi barging in, several shareholders present frowned.

But the secretary didn't bother to explain so much. He said breathlessly: "Dr. Zheng, they... they released the clinical trial data!"

As soon as these words came out, several shareholders present looked horrified.

Especially Dai Yang, he asked almost subconsciously: "Dr. Zheng, don't you say they have a guilty conscience? What is going on?"

When asked by Dai Yang, Zheng Yi's face turned red and white.

She just made some bold words here, saying that Lu Liang was too guilty to publish the data, but she never expected that as soon as she finished speaking, Lu Liang had already thrown the data in her face.

This made Zheng Yi feel a burning pain in her cheek.

(End of this chapter)